Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VERA
stocks logo

VERA

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
12 Analyst Rating
up Image0
Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 65.83 USD with a low forecast of 23.00 USD and a high forecast of 100.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 20.450
sliders
Low
23.00
Averages
65.83
High
100.00
up Image0
Current: 20.450
sliders
Low
23.00
Averages
65.83
High
100.00
Guggenheim
Buy
maintain
$61 -> $65
2025-06-03
Reason
Guggenheim
Price Target
$61 -> $65
2025-06-03
maintain
Buy
Reason
Guggenheim raised the firm's price target on Vera Therapeutics to $65 from $61 and keeps a Buy rating on the shares after the company reported "overwhelmingly positive" topline results from its pivotal Phase 3 ORIGIN 3 trial in IgA nephropathy. Following the data, the firm is increasing its view of the probability of success for atacicept to 90% from 85%, the analyst noted.
Scotiabank
Greg Harrison
Outperform
maintain
$55 -> $65
2025-06-03
Reason
Scotiabank
Greg Harrison
Price Target
$55 -> $65
2025-06-03
maintain
Outperform
Reason
Scotiabank analyst Greg Harrison raised the firm's price target on Vera Therapeutics to $65 from $55 and keeps an Outperform rating on the shares. The company recently reported positive topline data from the phase 3 ORIGIN trial of atacicept, with treatment using atacicept resulting in a 42% reduction in proteinuria compared to the placebo, the analyst tells investors. The firm overall believes the company is well positioned to capture a meaningful piece of the growing IgAN despite the competitive landscape.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$75 -> $85
2025-06-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$75 -> $85
2025-06-02
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Vera Therapeutics to $85 from $75 and keeps a Buy rating on the shares. The company reported "strong" topline data from the ongoing Phase 3 ORIGIN study evaluating atacicept for the treatment of immunoglobulin A nephropathy, the analyst tells investors in a research note. The firm says the drug demonstrated a 46% reduction from baseline in urine protein creatinine ratio, resulting in a statistically significant 42% reduction compared to placebo at week 36. The results not only confirm atacicept's therapeutic potential for IgAN treatment but also provide convincing evidence to support its best-in-class potential, contends H.C. Wainwright. It views the data as a "home run."
Scotiabank
NULL
to
Outperform
upgrade
$55 -> $65
2025-06-02
Reason
Scotiabank
Price Target
$55 -> $65
2025-06-02
upgrade
NULL
to
Outperform
Reason
Scotiabank raised the firm's price target on Vera Therapeutics to $65 from $55 and keeps an Outperform rating on the shares.
Scotiabank
Greg Harrison
Outperform -> Outperform
downgrade
$60 -> $55
2025-05-12
Reason
Scotiabank
Greg Harrison
Price Target
$60 -> $55
2025-05-12
downgrade
Outperform -> Outperform
Reason
Scotiabank analyst Greg Harrison lowered the firm's price target on Vera Therapeutics to $55 from $60 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors.
JP Morgan
Anupam Rama
Buy
Maintains
$77 → $71
2025-03-04
Reason
JP Morgan
Anupam Rama
Price Target
$77 → $71
2025-03-04
Maintains
Buy
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Vera Therapeutics to $71 from $77 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vera Therapeutics Inc (VERA.O) is -6.13, compared to its 5-year average forward P/E of -8.05. For a more detailed relative valuation and DCF analysis to assess Vera Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.05
Current PE
-6.13
Overvalued PE
-3.73
Undervalued PE
-12.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.10
Current EV/EBITDA
-3.67
Overvalued EV/EBITDA
-0.41
Undervalued EV/EBITDA
-9.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.85
Current PS
0.00
Overvalued PS
36.65
Undervalued PS
-26.95

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

VERA News & Events

Events Timeline

(ET)
2025-06-06
08:54:18
Vera Therapeutics drops 30% after rival Otsuka presents Phase 3 data
select
2025-06-02 (ET)
2025-06-02
06:32:40
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept
select
2025-05-06 (ET)
2025-05-06
08:05:44
Vera Therapeutics reports Q1 EPS (81c), consensus (78c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
08-04Benzinga
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

  • Analyst Downgrades: Several Wall Street analysts have downgraded ratings for various companies, including Allogene Therapeutics, AvalonBay Communities, Vera Therapeutics, and Shell plc, reflecting a shift in market outlook.

  • Stock Performance: The downgrades come with specific price target adjustments, indicating a cautious approach towards these stocks, with shares of Allogene closing at $1.08, AvalonBay at $184.44, Vera at $20.95, and Shell at $72.00.

Preview
5.0
07-11Newsfilter
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Inducement Awards Granted: Vera Therapeutics announced the granting of inducement awards to fifteen new employees, including non-qualified stock options for 133,500 shares and restricted stock units (RSUs) for 73,695 shares, as part of their Inducement Plan.

  • Company Overview: Vera Therapeutics is a biotechnology firm focused on developing treatments for serious immunological diseases, with lead products including atacicept and MAU868, aimed at addressing autoimmune conditions and viral infections.

Preview
6.5
07-03CNBC
These are JPMorgan’s favorite stocks heading into July

  • JPMorgan's Stock Picks: JPMorgan has added biotechnology firm Scholar Rock and construction supplies company Carlisle Companies to its top stock picks for July, while removing Vera Therapeutics and Alarm.com from the list. The updates come as U.S. stocks reached record highs in the first half of 2025.

  • Performance and Price Targets: Scholar Rock's shares have seen an 18% decline year-to-date but recently reported positive trial results, with a price target of $46 indicating a potential 29% upside. Carlisle Companies has gained about 7% in 2025, with a price target of $500 suggesting a 26% upside from its current price.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vera Therapeutics Inc (VERA) stock price today?

The current price of VERA is 20.45 USD — it has decreased -2.39 % in the last trading day.

arrow icon

What is Vera Therapeutics Inc (VERA)'s business?

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

arrow icon

What is the price predicton of VERA Stock?

Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 65.83 USD with a low forecast of 23.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vera Therapeutics Inc (VERA)'s revenue for the last quarter?

Vera Therapeutics Inc revenue for the last quarter amounts to -57.19M USD, increased 83.83 % YoY.

arrow icon

What is Vera Therapeutics Inc (VERA)'s earnings per share (EPS) for the last quarter?

Vera Therapeutics Inc. EPS for the last quarter amounts to -54593000.00 USD, increased 61.37 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vera Therapeutics Inc (VERA)'s fundamentals?

The market is revising No Change the revenue expectations for VERA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -19.90%.
arrow icon

How many employees does Vera Therapeutics Inc (VERA). have?

Vera Therapeutics Inc (VERA) has 112 emplpoyees as of August 05 2025.

arrow icon

What is Vera Therapeutics Inc (VERA) market cap?

Today VERA has the market capitalization of 1.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free